{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:05:21Z","timestamp":1789398321504,"version":"build-2803163510"},"reference-count":14,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that can affect patients\u2019 quality of life. Dupilumab is the first biologic agent approved for the treatment of patients with inadequately controlled moderate-to-severe AD and its mechanism of action is based on the inhibition of the interleukin (IL)-4 and IL-13 signaling. There are only a few data on the safety of dupilumab in AD patients with comorbidities, including kidney disorders. Materials and Methods: Descriptive retrospective series of three patients with chronic kidney diseases (Alport syndrome, IgA nephropathy, and hypertensive nephrosclerosis, respectively) receiving dupilumab for their concomitant severe AD. Results: Treatment with a standard dosage of dupilumab caused a relevant improvement of AD in all patients without any adverse events or worsening of renal function. In a patient with severe renal failure, the drug was effective and well tolerated without the need for any dose adjustments, also after the initiation of peritoneal dialytic treatment. Conclusion: Our case series suggests the use of dupilumab as an effective and safe treatment for AD patients suffering from renal diseases, although additional studies are required to confirm such preliminary findings.<\/jats:p>","DOI":"10.3390\/life12122002","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:46:41Z","timestamp":1669798001000},"page":"2002","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases"],"prefix":"10.3390","volume":"12","author":[{"given":"Caterina","family":"Foti","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Romita","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ambrogio","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Manno","sequence":"additional","affiliation":[{"name":"Section of Nefrology, Department of Emergency and Organ Transplantation (DETO), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Filotico","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Cassano","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology Private Practice, 76121 Barletta, Italy"},{"name":"Dermatology and Venerology Private Practice, 70100 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino Antonio","family":"Vena","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology Private Practice, 76121 Barletta, Italy"},{"name":"Dermatology and Venerology Private Practice, 70100 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"De Marco","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0325-4316","authenticated-orcid":false,"given":"Gerardo","family":"Cazzato","sequence":"additional","affiliation":[{"name":"Section of Pathology, Department of Emergency and Organ Transplantation (DETO), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagina Gisella","family":"Mennuni","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: A review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/DER.0000000000000845","article-title":"Systemic Therapy for Atopic Dermatitis in older adults and adults with comorbidities: A scoping review and international eczema council survey","volume":"33","author":"Drucker","year":"2022","journal-title":"Dermatitis"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Pulleiro, R., Garc\u00eda-Murias, M., Fidalgo-D\u00edaz, M., and Garc\u00eda-Gonz\u00e1lez, M.\u00c1. (2021). Molecular basis, diagnostic challenges and therapeutic approaches of alport syndrome: A primer for clinicians. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011063"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/jdv.17094","article-title":"DADE-dupilumab for atopic dermatitis of the elderly study group. dupilumab therapy of atopic dermatitis of the elderly: A multicentre, real-life study","volume":"35","author":"Patruno","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1159\/000518391","article-title":"chronic kidney disease-associated pruritus: A review","volume":"46","author":"Makar","year":"2021","journal-title":"Kidney Blood Press Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhai, L.L., Savage, K.T., Qiu, C.C., Jin, A., Valdes-Rodriguez, R., and Mollanazar, N.K. (2019). Chronic pruritus responding to dupilumab-a case series. Medicines, 6.","DOI":"10.3390\/medicines6030072"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/DER.0000000000000560","article-title":"treatment of atopic dermatitis with dupilumab in a renal transplant patient","volume":"31","author":"Kha","year":"2020","journal-title":"Dermatitis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/ced.15142","article-title":"Dupilumab in the management of atopic dermatitis in an immunosuppressed renal transplant patient","volume":"47","author":"Elamin","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jdcr.2019.08.023","article-title":"The utility of dupilumab for use in the pediatric population","volume":"5","author":"Varma","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"813313","DOI":"10.3389\/fmed.2022.813313","article-title":"Case report: The application of dupilumab in atopic dermatitis children complicated with nephrotic syndrome","volume":"9","author":"Yang","year":"2022","journal-title":"Front. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10157-018-1665-0","article-title":"T cells in IgA nephropathy: Role in pathogenesis, clinical significance and potential therapeutic target","volume":"23","author":"Ruszkowski","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.krcp.2016.07.002","article-title":"Elevated serum immunoglobulin E level as a marker for progression of immunoglobulin A nephropathy","volume":"35","author":"Lee","year":"2016","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"14708","DOI":"10.1111\/dth.14708","article-title":"Improvement of atopic dermatitis and IgA nephropathy in a patient treated by dupilumab","volume":"34","author":"Tanczosova","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jdcr.2022.01.009","article-title":"Exacerbation of IgA nephropathy in a patient receiving dupilumab","volume":"21","author":"Yamamoto","year":"2022","journal-title":"JAAD Case Rep."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/12\/2002\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:30:38Z","timestamp":1760146238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/12\/2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":14,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["life12122002"],"URL":"https:\/\/doi.org\/10.3390\/life12122002","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]}}}